New drug formulation brings hope of weekly jab for diabetics

Researchers from the University of Toronto have developed a new long-acting formulation of the incretin mimetic exenatide (Byetta®), which appears to offer better control of blood glucose levels than the current regimen of twice-daily injections. Thus, suggesting that it may soon be possible to control type 2 diabetes with a once-weekly injection. ... Continue Reading